Abbott's partner Freenome gets FDA approval for SimpleScreen
The test provides another screening option for up to 60 million unscreened eligible Americans, complementing existing Cologuard tests.
See the latest news and media coverage for Abbott. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global healthcare technology company
abbott.comLast updated
In short: Abbott exceeded Q2 2026 expectations, raising its profit guidance while securing key product approvals and managing multiple legal suits.
The test provides another screening option for up to 60 million unscreened eligible Americans, complementing existing Cologuard tests.
Sales reached $12.6 billion, driven by medical devices and diagnostics. The company projects accelerating growth in H2.
The unauthorized access was limited to internal systems and did not affect operations or the ability to serve patients. Abbott is investigating with help from cybersecurity experts and law enforcement.
The board declared a quarterly dividend of 63 cents per share, payable Aug. 17, 2026, marking 54 consecutive years of increases.
Abbott Laboratories Analyst Rating Update On October 17, 2023, UBS maintained a Buy rating on Abbott...
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics...
Abbott Laboratories (NYSE:ABT) has secured exclusive U.S. commercialization rights for Freenome's...
Track Abbott and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.